N-Oxide reduction by hemoglobin, cytochrome C and ferrous ions
- PMID: 6254119
Item in Clipboard
N-Oxide reduction by hemoglobin, cytochrome C and ferrous ions
Res Commun Chem Pathol Pharmacol.
1980 Oct.
Abstract
Indicine N-oxide is reduced to indicine by Fe(II) ions, by enzymatically reduced cytochrome c, and by ascorbic acid in conjunction with hemin or cytochrome c. Indicine N-oxide is not reduced by native hemoglobin, but is reduced by denatured hemoglobin. Oxygen competes with indicine N-oxide for reduction by denatured hemoglobin.
Similar articles
-
Metabolic conversion of indicine N-oxide to indicine in rabbits and humans.Cancer Res. 1979 Sep;39(9):3564-70. Cancer Res. 1979. PMID: 476682
-
Relationship of the reductive metabolism of indicine N-oxide to its antitumor activity.Res Commun Chem Pathol Pharmacol. 1979 Jun;24(3):559-69. Res Commun Chem Pathol Pharmacol. 1979. PMID: 451340
-
Quantitation of the antineoplastic agent indicine-N-oxide in human plasma by differential pulse polarography.J Pharm Sci. 1980 Jun;69(6):727-9. doi: 10.1002/jps.2600690632. J Pharm Sci. 1980. PMID: 7205594
-
The occurrence and analysis of pyrrolizidine alkaloid N-oxides.Xenobiotica. 1971 Jul-Oct;1(4):451-3. doi: 10.3109/00498257109041509. Xenobiotica. 1971. PMID: 4950834 Review. No abstract available.
-
Indicine N-oxide: clinical use of a pyrrolizidine alkaloid.Cancer Treat Rep. 1987 May;71(5):517-23. Cancer Treat Rep. 1987. PMID: 3552221 Review. No abstract available.
Cited by
-
Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.Cancer Metastasis Rev. 1993 Jun;12(2):119-34. doi: 10.1007/BF00689805. Cancer Metastasis Rev. 1993. PMID: 8375016 Review.
-
Improved translation of stability for conjugated antibodies using an in vitro whole blood assay.MAbs. 2020 Jan-Dec;12(1):1715705. doi: 10.1080/19420862.2020.1715705. MAbs. 2020. PMID: 31997712 Free PMC article.
-
Urinary metabolites of amitriptylinoxide and amitriptyline in single-dose experiments and during continuous therapy.Psychopharmacology (Berl). 1992;106(3):303-10. doi: 10.1007/BF02245409. Psychopharmacology (Berl). 1992. PMID: 1570375 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical